List view / Grid view
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
5 February 2015 | By The Institute of Cancer Research
A worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer...
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
21 November 2014 | By The Institute of Cancer Research
Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London
24 October 2014 | By The Institute of Cancer Research, London
Leading expert calls for major changes to restock pipeline with innovative cancer treatments...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
